vs
NORTECH SYSTEMS INC（NSYS）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
RECURSION PHARMACEUTICALS, INC.的季度营收约是NORTECH SYSTEMS INC的1.2倍（$35.5M vs $30.3M），NORTECH SYSTEMS INC净利率更高（3.0% vs -304.2%，领先307.2%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs 5.9%），NORTECH SYSTEMS INC自由现金流更多（$5.5M vs $-47.3M），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs -5.9%）
Nortech Systems Inc是一家全球电子制造服务提供商，为医疗科技、工业自动化、航空航天国防、交通运输等领域客户提供产品设计、原型制作、规模生产、供应链管理等全链路解决方案，主打符合行业规范的高可靠性电子组件与装配产品。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
NSYS vs RXRX — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $30.3M | $35.5M |
| 净利润 | $897.0K | $-108.1M |
| 毛利率 | 16.7% | 59.8% |
| 营业利润率 | 3.0% | -304.8% |
| 净利率 | 3.0% | -304.2% |
| 营收同比 | 5.9% | 681.7% |
| 净利润同比 | 160.7% | 39.6% |
| 每股收益（稀释后） | $0.32 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $30.3M | $35.5M | ||
| Q3 25 | $30.5M | $5.2M | ||
| Q2 25 | $30.7M | $19.2M | ||
| Q1 25 | $26.9M | $14.7M | ||
| Q4 24 | $28.6M | $4.5M | ||
| Q3 24 | $31.4M | $26.1M | ||
| Q2 24 | $33.9M | $14.4M | ||
| Q1 24 | $34.2M | $13.8M |
| Q4 25 | $897.0K | $-108.1M | ||
| Q3 25 | $-146.0K | $-162.3M | ||
| Q2 25 | $313.0K | $-171.9M | ||
| Q1 25 | $-1.3M | $-202.5M | ||
| Q4 24 | $-1.5M | $-178.9M | ||
| Q3 24 | $-739.0K | $-95.8M | ||
| Q2 24 | $157.0K | $-97.5M | ||
| Q1 24 | $765.0K | $-91.4M |
| Q4 25 | 16.7% | 59.8% | ||
| Q3 25 | 16.5% | -183.8% | ||
| Q2 25 | 15.8% | -4.9% | ||
| Q1 25 | 11.4% | -48.0% | ||
| Q4 24 | 9.9% | -181.4% | ||
| Q3 24 | 12.2% | 53.7% | ||
| Q2 24 | 13.6% | 36.2% | ||
| Q1 24 | 15.9% | 19.1% |
| Q4 25 | 3.0% | -304.8% | ||
| Q3 25 | 3.1% | -3327.6% | ||
| Q2 25 | 2.4% | -916.8% | ||
| Q1 25 | -6.0% | -1297.9% | ||
| Q4 24 | -4.3% | -4042.4% | ||
| Q3 24 | -1.5% | -377.1% | ||
| Q2 24 | 1.0% | -697.4% | ||
| Q1 24 | 3.4% | -698.4% |
| Q4 25 | 3.0% | -304.2% | ||
| Q3 25 | -0.5% | -3135.3% | ||
| Q2 25 | 1.0% | -894.2% | ||
| Q1 25 | -4.9% | -1373.3% | ||
| Q4 24 | -5.2% | -3935.5% | ||
| Q3 24 | -2.4% | -367.5% | ||
| Q2 24 | 0.5% | -676.6% | ||
| Q1 24 | 2.2% | -662.4% |
| Q4 25 | $0.32 | $-0.17 | ||
| Q3 25 | $-0.05 | $-0.36 | ||
| Q2 25 | $0.12 | $-0.41 | ||
| Q1 25 | $-0.48 | $-0.50 | ||
| Q4 24 | $-0.51 | $-0.56 | ||
| Q3 24 | $-0.27 | $-0.34 | ||
| Q2 24 | $0.05 | $-0.40 | ||
| Q1 24 | $0.26 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.7M | $743.3M |
| 总债务越低越好 | — | $9.6M |
| 股东权益账面价值 | $34.5M | $1.1B |
| 总资产 | $71.9M | $1.5B |
| 负债/权益比越低杠杆越低 | — | 0.01× |
8季度趋势，按日历期对齐
| Q4 25 | $1.7M | $743.3M | ||
| Q3 25 | $1.3M | $659.8M | ||
| Q2 25 | $652.0K | $525.1M | ||
| Q1 25 | $1.2M | $500.5M | ||
| Q4 24 | $916.0K | $594.4M | ||
| Q3 24 | $1.2M | $427.6M | ||
| Q2 24 | $1.5M | $474.3M | ||
| Q1 24 | $4.0M | $296.3M |
| Q4 25 | — | $9.6M | ||
| Q3 25 | — | $11.9M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $16.4M | ||
| Q4 24 | — | $19.0M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $22.9M | ||
| Q1 24 | — | — |
| Q4 25 | $34.5M | $1.1B | ||
| Q3 25 | $33.4M | $1.0B | ||
| Q2 25 | $33.4M | $919.1M | ||
| Q1 25 | $32.8M | $933.9M | ||
| Q4 24 | $34.0M | $1.0B | ||
| Q3 24 | $35.7M | $524.6M | ||
| Q2 24 | $36.1M | $584.4M | ||
| Q1 24 | $36.0M | $401.2M |
| Q4 25 | $71.9M | $1.5B | ||
| Q3 25 | $74.8M | $1.4B | ||
| Q2 25 | $74.8M | $1.3B | ||
| Q1 25 | $73.5M | $1.3B | ||
| Q4 24 | $72.4M | $1.4B | ||
| Q3 24 | $77.0M | $726.5M | ||
| Q2 24 | $76.3M | $775.9M | ||
| Q1 24 | $75.5M | $557.8M |
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $5.6M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | $5.5M | $-47.3M |
| 自由现金流率自由现金流/营收 | 18.0% | -133.1% |
| 资本支出强度资本支出/营收 | 0.5% | 3.5% |
| 现金转化率经营现金流/净利润 | 6.25× | — |
| 过去12个月自由现金流最近4个季度 | $2.1M | $-378.3M |
8季度趋势，按日历期对齐
| Q4 25 | $5.6M | $-46.1M | ||
| Q3 25 | $-92.0K | $-117.4M | ||
| Q2 25 | $157.0K | $-76.4M | ||
| Q1 25 | $-2.9M | $-132.0M | ||
| Q4 24 | $793.0K | $-115.4M | ||
| Q3 24 | $-1.6M | $-59.2M | ||
| Q2 24 | $-4.3M | $-82.2M | ||
| Q1 24 | $2.8M | $-102.3M |
| Q4 25 | $5.5M | $-47.3M | ||
| Q3 25 | $-242.0K | $-117.6M | ||
| Q2 25 | $58.0K | $-79.6M | ||
| Q1 25 | $-3.2M | $-133.8M | ||
| Q4 24 | $503.0K | $-116.7M | ||
| Q3 24 | $-1.6M | $-63.8M | ||
| Q2 24 | $-4.6M | $-83.4M | ||
| Q1 24 | $2.1M | $-109.0M |
| Q4 25 | 18.0% | -133.1% | ||
| Q3 25 | -0.8% | -2272.5% | ||
| Q2 25 | 0.2% | -413.9% | ||
| Q1 25 | -11.9% | -907.4% | ||
| Q4 24 | 1.8% | -2567.7% | ||
| Q3 24 | -5.2% | -244.6% | ||
| Q2 24 | -13.5% | -578.5% | ||
| Q1 24 | 6.1% | -789.9% |
| Q4 25 | 0.5% | 3.5% | ||
| Q3 25 | 0.5% | 4.7% | ||
| Q2 25 | 0.3% | 16.4% | ||
| Q1 25 | 1.0% | 12.4% | ||
| Q4 24 | 1.0% | 28.6% | ||
| Q3 24 | 0.1% | 17.5% | ||
| Q2 24 | 0.8% | 8.2% | ||
| Q1 24 | 2.2% | 48.2% |
| Q4 25 | 6.25× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.50× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -27.30× | — | ||
| Q1 24 | 3.70× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NSYS
| Medical Imaging | $11.4M | 37% |
| Medical Device | $8.0M | 26% |
| Industrial | $7.3M | 24% |
| Aerospace And Defense | $3.7M | 12% |
RXRX
暂无分部数据
